

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

June 17, 2025

To whom it may concern,

Company Name: DAICEL CORPORATION
Representative: Yasuhiro Sakaki, President and CEO
(Code: 4202, Prime Market of the Tokyo Stock Exchange)
Contact: Masahiko Hirokawa, Executive Officer, Deputy
General Manager, Corporate Support
Headquarters and General Manager, Investor
Relations & Corporate Communications
(Phone: +81-3-6711-8121)

(Corrections/ Corrections of Numerical Data) Partial corrections to the Consolidated Financial Results for the Year Ended March 31, 2025(Under Japanese GAAP)

DAICEL CORPORATION hereby announces that there have been corrections made to the “Consolidated Financial Results for the Fiscal Year Ended March 31, 2025[Japanese GAAP]” released on May 13, 2025. As numerical data has also been corrected, the corrected numerical data is also sent.

1. Reason for corrections

After the release of the “Consolidated Financial Results for the Year Ended March 31,2025 [Japanese GAAP]”, we have found errors in the “Investment in equity method investees” under “5. Consolidated Financial Statements (5) Notes to Consolidated Financial Statements (Segment Information)” and have corrected them.

2. Details of Corrections

The corrections are indicated with underlines.

5. Consolidated Financial Statements

(6) Notes to Consolidated Financial Statements (Segment Information)

3. Information on the amount of sales, profit or loss, assets and other items for each reportable segment

(Before corrections)

Year ended Mar. 31, 2024

(Unit: Millions of Yen)

	Medical / Healthcare	Smart	Safety	Materials	Engineering Plastics	Others	Total	Corporate and eliminations	Consolidated
Net sales									
Outside customers	13,927	33,814	95,574	182,242	226,821	5,676	558,056	—	558,056
Intersegment sales	—	7,352	—	3,757	152	13,682	24,946	(24,946)	—
Total	13,927	41,167	95,574	186,000	226,974	19,359	583,003	(24,946)	558,056
Operating profit (loss)	791	(897)	2,991	40,784	18,301	422	62,393	—	62,393
Assets	15,866	43,009	120,871	240,625	312,250	6,621	739,244	99,924	839,169
Other									
Depreciation	989	2,861	6,906	11,561	8,132	549	31,001	1,969	32,970
Amortization of goodwill	59	—	—	—	—	—	59	—	59
Investment in equity method investees	—	—	—	10	3	—	14	—	14
Capital expenditure	1,892	2,947	9,333	16,432	45,696	402	76,703	754	77,458

- (Note) 1. The category of “Others” is a business segment not included in reportable segments and includes the membrane business and the transportation warehousing business.
2. The reconciliation of segment assets consists of elimination of intersegment receivables of ¥(1,653) million and unallocated corporate assets of ¥101,578 million. Corporate assets consist of surplus operating funds (cash and deposits), long-term investment funds (investment securities), properties held or used by the administration departments, basic research departments, etc. and others.
3. There is no difference between total operating profit (loss) and operating profit in the consolidated statements of income.

Year ended Mar. 31, 2025

(Unit: Millions of Yen)

	Medical / Healthcare	Smart	Safety	Materials	Engineering Plastics	Others	Total	Corporate and eliminations	Consolidated
Net sales									
Outside customers	14,438	37,314	97,620	183,404	247,986	5,767	586,531	—	586,531
Intersegment sales	1	137	—	12,980	179	14,302	27,601	(27,601)	—
Total	14,439	37,451	97,620	196,385	248,165	20,069	614,133	(27,601)	586,531
Operating profit (loss)	261	(780)	3,931	29,626	27,006	965	61,011	—	61,011
Assets	15,427	38,659	130,651	229,891	325,812	5,694	746,137	67,693	813,831
Other									
Depreciation	1,015	2,565	6,933	18,791	9,387	619	39,313	1,639	40,952
Amortization of goodwill	18	—	—	—	—	—	18	—	18
Investment in equity method investees	—	—	—	10	5	—	15	—	15
Capital expenditure	880	1,990	10,736	9,953	43,235	304	67,101	2,359	69,461

- (Note) 1. The category of “Others” is a business segment not included in reportable segments and includes the membrane business and the transportation warehousing business.
2. The reconciliation of segment assets consists of elimination of intersegment receivables of ¥(6,558) million and unallocated corporate assets of ¥74,252 million. Corporate assets consist of surplus operating funds (cash and deposits), long-term investment funds (investment securities), properties held or used by the administration departments, basic research departments, etc. and others.
3. There is no difference between total operating profit (loss) and operating profit in the consolidated statements of income.

(After corrections)

Year ended Mar. 31, 2024

(Unit: Millions of Yen)

	Medical / Healthcare	Smart	Safety	Materials	Engineering Plastics	Others	Total	Corporate and eliminations	Consolidated
Net sales									
Outside customers	13,927	33,814	95,574	182,242	226,821	5,676	558,056	—	558,056
Intersegment sales	—	7,352	—	3,757	152	13,682	24,946	(24,946)	—
Total	13,927	41,167	95,574	186,000	226,974	19,359	583,003	(24,946)	558,056
Operating profit (loss)	791	(897)	2,991	40,784	18,301	422	62,393	—	62,393
Assets	15,866	43,009	120,871	240,625	312,250	6,621	739,244	99,924	839,169
Other									
Depreciation	989	2,861	6,906	11,561	8,132	549	31,001	1,969	32,970
Amortization of goodwill	59	—	—	—	—	—	59	—	59
Investment in equity method investees	—	—	—	10,485	3,658	—	14,143	—	14,143
Capital expenditure	1,892	2,947	9,333	16,432	45,696	402	76,703	754	77,458

- (Note) 1. The category of “Others” is a business segment not included in reportable segments and includes the membrane business and the transportation warehousing business.
2. The reconciliation of segment assets consists of elimination of intersegment receivables of ¥(1,653) million and unallocated corporate assets of ¥101,578 million. Corporate assets consist of surplus operating funds (cash and deposits), long-term investment funds (investment securities), properties held or used by the administration departments, basic research departments, etc. and others.
3. There is no difference between total operating profit (loss) and operating profit in the consolidated statements of income.

Year ended Mar. 31, 2025

(Unit: Millions of Yen)

	Medical / Healthcare	Smart	Safety	Materials	Engineering Plastics	Others	Total	Corporate and eliminations	Consolidated
Net sales									
Outside customers	14,438	37,314	97,620	183,404	247,986	5,767	586,531	—	586,531
Intersegment sales	1	137	—	12,980	179	14,302	27,601	(27,601)	—
Total	14,439	37,451	97,620	196,385	248,165	20,069	614,133	(27,601)	586,531
Operating profit (loss)	261	(780)	3,931	29,626	27,006	965	61,011	—	61,011
Assets	15,427	38,659	130,651	229,891	325,812	5,694	746,137	67,693	813,831
Other									
Depreciation	1,015	2,565	6,933	18,791	9,387	619	39,313	1,639	40,952
Amortization of goodwill	18	—	—	—	—	—	18	—	18
Investment in equity method investees	—	—	—	10,087	5,801	—	15,889	—	15,889
Capital expenditure	880	1,990	10,736	9,953	43,235	304	67,101	2,359	69,461

- (Note) 1. The category of “Others” is a business segment not included in reportable segments and includes the membrane business and the transportation warehousing business.
2. The reconciliation of segment assets consists of elimination of intersegment receivables of ¥(6,558) million and unallocated corporate assets of ¥74,252 million. Corporate assets consist of surplus operating funds (cash and deposits), long-term investment funds (investment securities), properties held or used by the administration departments, basic research departments, etc. and others.
3. There is no difference between total operating profit (loss) and operating profit in the consolidated statements of income.